Clyde Yancy, MD, FAHA, past president of the American Heart Association comments on the results of DELIVER, which found that among individuals with heart failure and a mildly reduced or preserved ejection fraction, dapagliflozin reduced the combined risk of worsening heart failure or cardiovascular death.